isoniazid has been researched along with AIDS Seroconversion in 56 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although antiretroviral therapy (ART) can avert tuberculosis (TB) incidence among human immunodeficiency virus (HIV) infected patients, the concomitant use of ART with isoniazid (INH) has a paramount effect." | 8.12 | Tuberculosis and isoniazid prophylaxis among adult HIV positive patients on ART in Northwest Ethiopia. ( Adem, M; Bayleyegn, B; Geremew, D; Geremew, H; Tamir, M; Tegene, B, 2022) |
| "The aims of this study were to (1) identify trends and risk factors for mycobacterial disease and (2) determine the effect of expanded access to isoniazid chemoprophylaxis on tuberculosis incidence." | 5.08 | Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. ( Astemborski, J; Bonds, M; Galai, N; Graham, NM; Nelson, KE; Rizzo, RT; Sheeley, L; Vlahov, D, 1996) |
| "Although antiretroviral therapy (ART) can avert tuberculosis (TB) incidence among human immunodeficiency virus (HIV) infected patients, the concomitant use of ART with isoniazid (INH) has a paramount effect." | 4.12 | Tuberculosis and isoniazid prophylaxis among adult HIV positive patients on ART in Northwest Ethiopia. ( Adem, M; Bayleyegn, B; Geremew, D; Geremew, H; Tamir, M; Tegene, B, 2022) |
| "A switch of continuation phase tuberculosis (TB) treatment regimen from Ethambutol (E) and Isoniazid (H) combination for 6 months (6EH) to Rifampicin (R) and Isoniazid (H) combination for 4 months (4RH) was recommended." | 3.83 | Tuberculosis treatment outcomes of six and eight month treatment regimens in districts of Southwestern Ethiopia: a comparative cross-sectional study. ( Asres, A; Deressa, W; Jerene, D, 2016) |
| "Isoniazide preventive therapy (IPT) is given to individuals with latent infection of tuberculosis (TB) to prevent the progression to active disease." | 3.77 | Predictors of adherence to isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia. ( Biadgilign, S; Deribew, A; Mindachew, M; Tessema, F, 2011) |
| " Peak drug exposure to isoniazid was lower in patients with diarrhea." | 3.69 | Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. ( Cameron, DW; Gallicano, K; Garber, G; Oliveras, L; Rachlis, A; Sahai, J; Seguin, I; Swick, L; Tailor, S; Walker, S, 1997) |
| " We investigated the incidence of adverse events and cure rates according to HIV status for patients receiving standard TB therapy in the trial." | 2.90 | Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status. ( Crook, AM; Dawson, R; Diacon, AH; Gillespie, SH; McHugh, TD; Mendel, CM; Meredith, SK; Mohapi, L; Murphy, ME; Nunn, AJ; Phillips, PPJ; Singh, KP; Spigelman, M; Tweed, CD, 2019) |
| "Prophylaxis against tuberculosis has been recognized as important for preventing clinical forms of tuberculosis, mainly in HIV positive patients." | 2.73 | [Effectiveness of prophylaxis against tuberculosis in patients infected with HIV]. ( Arbeláez, A; Arbeláez, MP; Arias, SL; Betancourt, G; Gómez, RD; Nagles, J; Peláez, LM; Rojas, C; Velásquez, G; Vélez, L, 2007) |
| "Optimum treatment of tuberculosis in persons with human immunodeficiency virus (HIV) infection is still being defined." | 2.38 | Failure of therapy for tuberculosis in human immunodeficiency virus infection. ( Nolan, CM, 1992) |
| "Tuberculosis is on the increase in the United States, so physicians would be prudent to renew familiarity with the disease." | 2.38 | Tuberculosis makes a comeback. Giving and interpreting the Mantoux test. ( Dickensheets, DL, 1989) |
| "All grade 3 & 4 adverse events (AEs) and their relationship to treatment for patients who had taken at least one dose of therapy in the REMoxTB clinical trial were recorded." | 1.48 | Toxicity associated with tuberculosis chemotherapy in the REMoxTB study. ( Amukoye, EI; Crook, AM; Dawson, R; Diacon, AH; Gillespie, SH; Hanekom, M; McHugh, TD; Mendel, CM; Meredith, SK; Murphy, ME; Murthy, SE; Nunn, AJ; Phillips, PPJ; Singh, KP; Spigelman, M; Tweed, CD; Wills, GH, 2018) |
| "Half the recurrences occurred in the first year since completing treatment." | 1.38 | The impact of HIV and ART on recurrent tuberculosis in a sub-Saharan setting. ( Crampin, AC; French, N; Glynn, JR; Houben, RM; Mboma, S; Mpunga, J; Mwaungulu, L; Mwaungulu, NJ; Mwenibabu, M; Mzemba, T, 2012) |
| "Major adverse reactions to antituberculosis drugs can cause significant morbidity, and compromise treatment regimens for tuberculosis (TB)." | 1.32 | Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. ( Menzies, D; Parisien, I; Pelletier, M; Rocher, I; Valiquette, C; Yee, D, 2003) |
| "Ethambutol was recovered from human urine quantitatively and stable for a period of at least one week in urine stored at -20 degrees C." | 1.32 | Standardization of the method for estimation of ethambutol in pharmaceutical preparations and biological fluid. ( Bhagavathy, S; Gayathri, TN; Gurumurthy, P; Venkatesan, P, 2004) |
| "The decision was analyzed for an intravenous drug abuser who may have been anergic, while tuberculin test status, race, and gender were varied." | 1.28 | Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis. ( Jordan, TJ; Lewit, EM; Montgomery, RL; Reichman, LB, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.79) | 18.7374 |
| 1990's | 27 (48.21) | 18.2507 |
| 2000's | 10 (17.86) | 29.6817 |
| 2010's | 14 (25.00) | 24.3611 |
| 2020's | 4 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Geremew, D | 1 |
| Geremew, H | 1 |
| Tamir, M | 1 |
| Adem, M | 1 |
| Tegene, B | 1 |
| Bayleyegn, B | 1 |
| Sekayi, W | 1 |
| Namyalo, E | 1 |
| Namayanja, J | 1 |
| Kungu, JM | 1 |
| Tweed, CD | 2 |
| Crook, AM | 3 |
| Dawson, R | 2 |
| Diacon, AH | 2 |
| McHugh, TD | 4 |
| Mendel, CM | 3 |
| Meredith, SK | 3 |
| Mohapi, L | 1 |
| Murphy, ME | 2 |
| Nunn, AJ | 4 |
| Phillips, PPJ | 2 |
| Singh, KP | 2 |
| Spigelman, M | 2 |
| Gillespie, SH | 4 |
| Peetluk, LS | 1 |
| Rebeiro, PF | 1 |
| Cordeiro-Santos, M | 1 |
| Kritski, A | 1 |
| Andrade, BB | 1 |
| Durovni, B | 1 |
| Calvacante, S | 1 |
| Arriaga, MB | 1 |
| Turner, MM | 1 |
| Figueiredo, MC | 1 |
| Rolla, VC | 1 |
| Sterling, TR | 1 |
| Alemu, A | 1 |
| Yesuf, A | 1 |
| Zerihun, B | 1 |
| Getu, M | 1 |
| Worku, T | 1 |
| Bitew, ZW | 1 |
| Thindwa, D | 1 |
| MacPherson, P | 1 |
| Choko, AT | 1 |
| Khundi, M | 1 |
| Sambakunsi, R | 1 |
| Ngwira, LG | 1 |
| Kalua, T | 1 |
| Webb, EL | 1 |
| Corbett, EL | 1 |
| Amukoye, EI | 1 |
| Hanekom, M | 1 |
| Murthy, SE | 1 |
| Wills, GH | 1 |
| Soborg, C | 1 |
| Ruhwald, M | 1 |
| Andersen, PH | 1 |
| Ravn, P | 1 |
| Murray, SR | 1 |
| Pappas, F | 1 |
| Phillips, PP | 2 |
| Jindani, A | 1 |
| Harrison, TS | 1 |
| Churchyard, GJ | 1 |
| Charalambous, S | 1 |
| Hatherill, M | 1 |
| Geldenhuys, H | 1 |
| McIlleron, HM | 1 |
| Zvada, SP | 1 |
| Mungofa, S | 1 |
| Shah, NA | 1 |
| Zizhou, S | 1 |
| Magweta, L | 1 |
| Shepherd, J | 1 |
| Nyirenda, S | 1 |
| van Dijk, JH | 1 |
| Clouting, HE | 1 |
| Coleman, D | 1 |
| Bateson, AL | 1 |
| Butcher, PD | 1 |
| Mitchison, DA | 2 |
| Abdool Karim, SS | 1 |
| Despotovic, A | 1 |
| Savic, B | 1 |
| Salemovic, D | 1 |
| Ranin, J | 1 |
| Jevtovic, D | 1 |
| Asres, A | 1 |
| Jerene, D | 1 |
| Deressa, W | 1 |
| Asiimwe, BB | 1 |
| Ghebremichael, S | 1 |
| Kallenius, G | 1 |
| Koivula, T | 1 |
| Joloba, ML | 1 |
| Sar, B | 1 |
| Keo, C | 1 |
| Leng, C | 1 |
| Saman, M | 1 |
| Min, DC | 1 |
| Chan, S | 1 |
| Monchy, D | 1 |
| Sarthou, JL | 1 |
| Cohen, T | 1 |
| Murray, M | 1 |
| Wallengren, K | 1 |
| Alvarez, GG | 1 |
| Samuel, EY | 1 |
| Wilson, D | 1 |
| Khajotia, R | 1 |
| Manthari, K | 1 |
| Tripathy, S | 1 |
| Anand, A | 1 |
| Inamdar, V | 1 |
| Manoj, MM | 1 |
| Khillare, KM | 1 |
| Datye, AS | 1 |
| Iyer, R | 1 |
| Kanoj, DM | 1 |
| Thakar, M | 1 |
| Kale, V | 1 |
| Pereira, M | 1 |
| Risbud, AR | 1 |
| Mindachew, M | 1 |
| Deribew, A | 1 |
| Tessema, F | 1 |
| Biadgilign, S | 1 |
| Houben, RM | 1 |
| Glynn, JR | 2 |
| Mboma, S | 1 |
| Mzemba, T | 1 |
| Mwaungulu, NJ | 1 |
| Mwaungulu, L | 1 |
| Mwenibabu, M | 1 |
| Mpunga, J | 1 |
| French, N | 1 |
| Crampin, AC | 1 |
| Chakaya, JM | 1 |
| Kibuga, D | 1 |
| Ng'ang'a, L | 1 |
| Githui, WA | 1 |
| Mansoer, JR | 1 |
| Gakiria, G | 1 |
| Kwamanga, D | 1 |
| Maende, J | 1 |
| Yee, D | 1 |
| Valiquette, C | 1 |
| Pelletier, M | 1 |
| Parisien, I | 1 |
| Rocher, I | 1 |
| Menzies, D | 1 |
| Gurumurthy, P | 1 |
| Gayathri, TN | 1 |
| Bhagavathy, S | 1 |
| Venkatesan, P | 1 |
| Ramachandran, G | 1 |
| Hemanth Kumar, AK | 1 |
| Sarala, K | 1 |
| Padmapriyadarsini, C | 1 |
| Anitha, S | 1 |
| Tharani, CB | 1 |
| Kumaraswami, V | 1 |
| Swaminathan, S | 1 |
| Arbeláez, MP | 1 |
| Arbeláez, A | 1 |
| Gómez, RD | 1 |
| Rojas, C | 1 |
| Vélez, L | 1 |
| Arias, SL | 1 |
| Nagles, J | 1 |
| Peláez, LM | 1 |
| Betancourt, G | 1 |
| Velásquez, G | 1 |
| Masobe, P | 1 |
| Lee, T | 1 |
| Price, M | 1 |
| Hawken, M | 1 |
| Nunn, P | 1 |
| Gathua, S | 1 |
| Brindle, R | 1 |
| Godfrey-Faussett, P | 1 |
| Githui, W | 1 |
| Odhiambo, J | 1 |
| Batchelor, B | 1 |
| Gilks, C | 1 |
| Morris, J | 1 |
| Chintu, C | 1 |
| Bhat, G | 1 |
| Luo, C | 1 |
| Raviglione, M | 1 |
| Diwan, V | 1 |
| Dupont, HL | 1 |
| Zumla, A | 1 |
| Trautmann, M | 1 |
| Ruhnke, M | 1 |
| Held, T | 1 |
| Weinke, T | 1 |
| Pape, JW | 1 |
| Jean, SS | 1 |
| Ho, JL | 1 |
| Hafner, A | 1 |
| Johnson, WD | 1 |
| Kennedy, N | 1 |
| Fox, R | 1 |
| Kisyombe, GM | 1 |
| Saruni, AO | 1 |
| Uiso, LO | 1 |
| Ramsay, AR | 1 |
| Ngowi, FI | 1 |
| Neville, K | 1 |
| Bromberg, A | 1 |
| Bromberg, R | 1 |
| Bonk, S | 1 |
| Hanna, BA | 1 |
| Rom, WN | 1 |
| Schürmann, D | 1 |
| Bergmann, F | 1 |
| Jautzke, G | 1 |
| Fehrenbach, J | 1 |
| Mauch, H | 1 |
| Ruf, B | 1 |
| Delaney, V | 1 |
| Sumrani, N | 1 |
| Hong, JH | 1 |
| Sommer, B | 1 |
| Kassim, S | 1 |
| Sassan-Morokro, M | 1 |
| Ackah, A | 1 |
| Abouya, LY | 1 |
| Digbeu, H | 1 |
| Yesso, G | 1 |
| Coulibaly, IM | 1 |
| Coulibaly, D | 1 |
| Whitaker, PJ | 1 |
| Doorly, R | 1 |
| Brook, MG | 1 |
| Miller, RF | 1 |
| Suwanagool, S | 1 |
| Chuenarom, V | 1 |
| Pechthanon, L | 1 |
| Sonjai, A | 1 |
| Leelarasamee, A | 1 |
| Pathrakom, C | 1 |
| Ausina, V | 1 |
| Graham, NM | 1 |
| Galai, N | 1 |
| Nelson, KE | 1 |
| Astemborski, J | 1 |
| Bonds, M | 1 |
| Rizzo, RT | 1 |
| Sheeley, L | 1 |
| Vlahov, D | 1 |
| Sahai, J | 1 |
| Gallicano, K | 1 |
| Swick, L | 1 |
| Tailor, S | 1 |
| Garber, G | 1 |
| Seguin, I | 1 |
| Oliveras, L | 1 |
| Walker, S | 1 |
| Rachlis, A | 1 |
| Cameron, DW | 1 |
| Bock, NN | 1 |
| Metzger, BS | 1 |
| Tapia, JR | 1 |
| Blumberg, HM | 1 |
| Topley, JM | 1 |
| Bamber, S | 1 |
| Coovadia, HM | 1 |
| Corr, PD | 1 |
| Snyder, DC | 1 |
| Paz, EA | 1 |
| Mohle-Boetani, JC | 1 |
| Fallstad, R | 1 |
| Black, RL | 1 |
| Chin, DP | 1 |
| Warndorff, DK | 1 |
| Yates, M | 1 |
| Ngwira, B | 1 |
| Chagaluka, S | 1 |
| Jenkins, PA | 1 |
| Drobniewski, F | 1 |
| Pönnighaus, JM | 1 |
| Fine, PE | 1 |
| Perlman, DC | 1 |
| Gourevitch, MN | 1 |
| Trinh, C | 1 |
| Salomon, N | 1 |
| Horn, L | 1 |
| Des Jarlais, DC | 1 |
| Kingston, M | 1 |
| Childs, K | 1 |
| Carlin, E | 1 |
| Veeken, H | 1 |
| Bermejo, A | 1 |
| Nolan, CM | 1 |
| Shafer, RW | 1 |
| Chirgwin, KD | 1 |
| Glatt, AE | 1 |
| Dahdouh, MA | 1 |
| Landesman, SH | 1 |
| Suster, B | 1 |
| Figg, WD | 1 |
| Jordan, TJ | 1 |
| Lewit, EM | 1 |
| Montgomery, RL | 1 |
| Reichman, LB | 1 |
| Dickensheets, DL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised Placebo - Controlled Double Blind Trial Comparing 1) a Two Month Intensive Phase of Ethambutol, Moxifloxacin, Rifampicin, Pyrazinamide Versus the Standard Regimen (Ethambutol, Isoniazid, Rifampicin, Pyrazinamide) and 2) a Treatment Shortening[NCT00864383] | Phase 3 | 1,931 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Using Biomarkers to Predict TB Treatment Duration[NCT02821832] | Phase 2 | 946 participants (Actual) | Interventional | 2017-06-21 | Active, not recruiting | ||
| A Prospective, Randomized Controlled Study for the Efficacy and Safety of the Substitution of Pyrazinamide and Ethambutol With Moxifloxacin During the Intensive Phase of Treatment of Pulmonary Tuberculosis[NCT04187469] | 286 participants (Anticipated) | Interventional | 2020-03-01 | Not yet recruiting | |||
| Z 31411 - The Effect of Xpert MTB/RIF on Patient Health Outcomes and Empirical TB Treatment Among Persons Living With HIV/AIDS: A Parallel-Group Prospective Cohort Study Under Real-World Conditions in Lusaka, Zambia[NCT02729532] | 776 participants (Actual) | Observational | 2016-06-22 | Completed | |||
| Adaptive Evaluation of mHealth and Conventional Adherence Support Interventions to Optimize Outcome With New Treatment Regimens for Drug-resistant Tuberculosis and HIV in South Africa[NCT05633056] | 360 participants (Anticipated) | Interventional | 2023-02-28 | Not yet recruiting | |||
| Randomized Clinical Trial to Assess the Efficacy of Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis[NCT00376012] | Phase 3 | 300 participants (Actual) | Interventional | 2001-02-28 | Active, not recruiting | ||
| TB Treatment Support Tools: Refinement and Evaluation of an Interactive Mobile App and Direct Adherence Monitoring on TB Treatment Outcomes[NCT04221789] | 555 participants (Actual) | Interventional | 2020-11-17 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The secondary analysis of efficacy outcome was the proportion of patients who had bacteriologically or clinically defined failure or relapse within 18 months after randomization (a composite unfavorable outcome) based on MGIT. Culture-negative status was defined as two negative-culture results at different visits without an intervening positive result. The date of culture-negative status was defined as the date of the first negative-culture result. This status continued until there were two positive cultures, without an intervening negative culture, or until there was a single positive culture that was not followed by two negative cultures. Relapse strains were those shown to be identical on 24-locus Mycobacterial interspersed repetitive units (MIRU) analysis. (NCT00864383)
Timeframe: 18 months (within one year of completion of therapy)
| Intervention | participants with failure or relapse (Number) |
|---|---|
| Regimen 1 - 2EHRZ/4HR (Control Regimen) | 65 |
| Regimen 2 - 2MHRZ/2MHR | 98 |
| Regimen 3 - 2EMRZ/2MR | 131 |
The primary efficacy outcome was the proportion of patients who had bacteriologically or clinically defined failure or relapse within 18 months after randomization (a composite unfavorable outcome). Culture-negative status was defined as two negative-culture results at different visits without an intervening positive result. The date of culture-negative status was defined as the date of the first negative-culture result. This status continued until there were two positive cultures, without an intervening negative culture, or until there was a single positive culture that was not followed by two negative cultures. Relapse strains were those shown to be identical on 24-locus Mycobacterial interspersed repetitive units (MIRU) analysis. For the final 18 month study visit when both L-J samples were contaminated or missing, if the subject could not be brought back, liquid medium culture results were used in place of solid medium culture results. (NCT00864383)
Timeframe: 18 months (within one year of completion of therapy)
| Intervention | participants with failure or relapse (Number) |
|---|---|
| Regimen 1 - 2EHRZ/4HR (Control Regimen) | 43 |
| Regimen 2 - 2MHRZ/2MHR | 78 |
| Regimen 3 - 2EMRZ/2MR | 105 |
Number of patients who are TB MGIT culture negative at 8 weeks. (NCT00864383)
Timeframe: 8 weeks
| Intervention | participants who are culture negative (Number) |
|---|---|
| Regimen 1 - 2EHRZ/4HR (Control Regimen) | 235 |
| Regimen 2 - 2MHRZ/2MHR | 274 |
| Regimen 3 - 2EMRZ/2MR | 260 |
Number of patients who are TB LJ culture negative at 8 weeks. (NCT00864383)
Timeframe: 8 weeks
| Intervention | participants who are culture negative (Number) |
|---|---|
| Regimen 1 - 2EHRZ/4HR (Control Regimen) | 352 |
| Regimen 2 - 2MHRZ/2MHR | 394 |
| Regimen 3 - 2EMRZ/2MR | 401 |
The number of participants includes all patients who had at least one grade 3 or 4 adverse event. (NCT00864383)
Timeframe: 18 months (within one year of completion of therapy)
| Intervention | participants with Grade 3 or 4 AEs (Number) |
|---|---|
| Regimen 1 - 2EHRZ/4HR (Control Regimen) | 123 |
| Regimen 2 - 2MHRZ/2MHR | 127 |
| Regimen 3 - 2EMRZ/2MR | 111 |
"Sensitivity Analysis of Primary Efficacy Results of All Randomized Subjects Imputing Favorable for Missing Outcomes. Analysis is the number of subjects with an unfavorable outcome. Favorable outcome is defined as the number of subjects with a negative TB culture status at 18 months (at or after 72 weeks), who had not already been classified as having an unfavorable outcome, and whose last positive TB culture result (isolated positive culture) was followed by at least two negative culture results." (NCT00864383)
Timeframe: 18 months
| Intervention | participants with unfavorable outcome (Number) |
|---|---|
| Regimen 1 - 2EHRZ/4HR (Control Regimen) | 87 |
| Regimen 2 - 2MHRZ/2MHR | 132 |
| Regimen 3 - 2EMRZ/2MR | 132 |
"Sensitivity Analysis of Primary Efficacy Results of All Randomized Subjects Imputing Unfavorable for Missing Outcomes. Analysis is the number of subjects with an unfavorable outcome. Favorable outcome is defined as the number of subjects with a negative TB culture status at 18 months (at or after 72 weeks), who had not already been classified as having an unfavorable outcome, and whose last positive TB culture result (isolated positive culture) was followed by at least two negative culture results." (NCT00864383)
Timeframe: 18 months
| Intervention | participants with unfavorable outcome (Number) |
|---|---|
| Regimen 1 - 2EHRZ/4HR (Control Regimen) | 172 |
| Regimen 2 - 2MHRZ/2MHR | 219 |
| Regimen 3 - 2EMRZ/2MR | 217 |
Culture negative for TB using LJ cultures. (NCT00864383)
Timeframe: 18 months
| Intervention | Time to culture negative status / weeks (Median) |
|---|---|
| Regimen 1 - 2EHRZ/4HR (Control Regimen) | 6.0 |
| Regimen 2 - 2MHRZ/2MHR | 6.0 |
| Regimen 3 - 2EMRZ/2MR | 6.0 |
(NCT00864383)
Timeframe: 18 months
| Intervention | Time to culture negative status / weeks (Median) |
|---|---|
| Regimen 1 - 2EHRZ/4HR (Control Regimen) | 11.9 |
| Regimen 2 - 2MHRZ/2MHR | 8.0 |
| Regimen 3 - 2EMRZ/2MR | 8.0 |
Estimation of the lower bound of a one-sided 95% confidence interval of the difference in success rates between arms B and C. If the lower bound is greater than -7%, this will be evidence that the treatment-shortening arm is not inferior to the standard duration arm. (NCT02821832)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Cured | Confirmed relapses | Late withdrawal, lost to follow-up | Probable relapses | Treatment Failure | |
| Arm A | 217 | 5 | 13 | 1 | 1 |
| Arm B | 121 | 1 | 9 | 1 | 0 |
| Arm C | 117 | 9 | 6 | 3 | 4 |
5 reviews available for isoniazid and AIDS Seroconversion
| Article | Year |
|---|---|
Complicated tuberculosis and residual disease.
Topics: HIV Seropositivity; Humans; Isoniazid; Recurrence; Risk Factors; Tuberculosis; Tuberculosis, Pulmona | 1994 |
Prevention and management of tuberculosis in HIV positive patients living in countries with a low prevalence of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Cross Infection; Emigration and Immigration; Ethambutol; HIV Seropositivity; | 1996 |
The impact of the HIV epidemic on tuberculosis control programmes in developing countries.
Topics: Acquired Immunodeficiency Syndrome; BCG Vaccine; Child; Child, Preschool; Contraindications; Develop | 1992 |
Failure of therapy for tuberculosis in human immunodeficiency virus infection.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Drug Therapy, Combi | 1992 |
Tuberculosis makes a comeback. Giving and interpreting the Mantoux test.
Topics: Adult; Age Factors; False Negative Reactions; HIV Seropositivity; Humans; Hypersensitivity, Delayed; | 1989 |
9 trials available for isoniazid and AIDS Seroconversion
| Article | Year |
|---|---|
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status.
Topics: Adult; Antitubercular Agents; Ethambutol; Female; HIV Seropositivity; Humans; Incidence; Isoniazid; | 2019 |
Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi.
Topics: Adolescent; Adult; Anti-Retroviral Agents; Antitubercular Agents; CD4 Lymphocyte Count; Female; HIV | 2018 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Administration Schedule; Drug Therapy, C | 2014 |
[Effectiveness of prophylaxis against tuberculosis in patients infected with HIV].
Topics: Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Cohort Studies; Comorbidity; Fe | 2007 |
Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Drug Therapy, Comb | 1993 |
Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.
Topics: Adult; Aged; Ciprofloxacin; Drug Therapy, Combination; Ethambutol; Female; HIV Seropositivity; HIV-1 | 1993 |
Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa.
Topics: Adolescent; Adult; Africa, Western; AIDS-Related Opportunistic Infections; Antibiotics, Antitubercul | 1995 |
Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease.
Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotic Prophylaxis; Antitubercular Agents; Female; | 1996 |
42 other studies available for isoniazid and AIDS Seroconversion
| Article | Year |
|---|---|
Tuberculosis and isoniazid prophylaxis among adult HIV positive patients on ART in Northwest Ethiopia.
Topics: Adult; Antitubercular Agents; Ethiopia; HIV Infections; HIV Seropositivity; Humans; Incidence; Isoni | 2022 |
Prevalence and predictors of tuberculosis among HIV patients who completed isoniazid preventive therapy (IPT) at Reach out Mbuya community health initiative.
Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; HIV; HIV Infections; HIV Seropositivity; Huma | 2023 |
Lack of Weight Gain During the First 2 Months of Treatment and Human Immunodeficiency Virus Independently Predict Unsuccessful Treatment Outcomes in Tuberculosis.
Topics: Adult; Antitubercular Agents; Brazil; Ethambutol; Female; HIV Seropositivity; Humans; Isoniazid; Mal | 2020 |
Incidence and determinants of tuberculosis among HIV-positive individuals in Addis Ababa, Ethiopia: A retrospective cohort study.
Topics: Adolescent; Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Disease-Free Survival; Ethio | 2020 |
Toxicity associated with tuberculosis chemotherapy in the REMoxTB study.
Topics: Adult; Antitubercular Agents; Clinical Protocols; Ethambutol; Female; HIV Seropositivity; Humans; In | 2018 |
6-year follow-up of 522 HIV-positive individuals screened for Mycobacterium tuberculosis infection in Denmark.
Topics: Cohort Studies; Communicable Disease Control; Denmark; Diagnostic Tests, Routine; Female; Follow-Up | 2014 |
Overcoming Impediments to Global Implementation of Early Antiretroviral Therapy.
Topics: AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Female; HIV In | 2015 |
Isoniazid-resistant Mycobacterium kansasii in an HIV-positive patient, and possible development of immune reconstitution inflammatory syndrome after initiation of highly active antiretroviral therapy: case report.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; HIV Seropositivity; Humans; Imm | 2016 |
Tuberculosis treatment outcomes of six and eight month treatment regimens in districts of Southwestern Ethiopia: a comparative cross-sectional study.
Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; Drug Therapy, Combination; Ethambutol; Ethiop | 2016 |
Mycobacterium tuberculosis spoligotypes and drug susceptibility pattern of isolates from tuberculosis patients in peri-urban Kampala, Uganda.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antibodies, Bacterial; Bacterial Typing Techniques; | 2008 |
Anti-tuberculosis drug resistance and HIV co-infection in Phnom Penh, Cambodia.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Cambodia; HIV Infections; HIV Seroposi | 2009 |
The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Autopsy; Drug Resistance, Bacte | 2010 |
The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Autopsy; Drug Resistance, Bacte | 2010 |
The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Autopsy; Drug Resistance, Bacte | 2010 |
The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Autopsy; Drug Resistance, Bacte | 2010 |
An apparently healthy young man with a peculiar-looking chest radiograph.
Topics: Adult; Antibiotics, Antitubercular; Drug Therapy, Combination; Ethambutol; Fever; HIV Seropositivity | 2011 |
Clinical response of newly diagnosed HIV seropositive & seronegative pulmonary tuberculosis patients with the RNTCP Short Course regimen in Pune, India.
Topics: Adult; Antitubercular Agents; Communicable Disease Control; Directly Observed Therapy; Enzyme-Linked | 2011 |
Predictors of adherence to isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia.
Topics: Adult; Aged; Antitubercular Agents; Cross-Sectional Studies; Ethiopia; Female; Forecasting; HIV Sero | 2011 |
The impact of HIV and ART on recurrent tuberculosis in a sub-Saharan setting.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; CD | 2012 |
Tuberculosis re-treatment outcomes within the public service in Nairobi, Kenya.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Antitubercular Ag | 2002 |
Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug In | 2003 |
Standardization of the method for estimation of ethambutol in pharmaceutical preparations and biological fluid.
Topics: Antitubercular Agents; Chemistry, Clinical; Chromatography; Dose-Response Relationship, Drug; Ethamb | 2004 |
Urine levels of rifampicin & isoniazid in asymptomatic HIV-positive individuals.
Topics: Adult; Antitubercular Agents; CD4-Positive T-Lymphocytes; Drug Administration Schedule; Drug Resista | 2007 |
Isoniazid prophylactic therapy for tuberculosis in HIV-seropositive patients--a least-cost analysis.
Topics: Ambulatory Care; Computer Simulation; Cost of Illness; Costs and Cost Analysis; Feasibility Studies; | 1995 |
Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitu | 1993 |
Seroprevalence of human immunodeficiency virus type 1 infection in Zambian children with tuberculosis.
Topics: Adolescent; AIDS-Related Opportunistic Infections; BCG Vaccine; Child; Child, Preschool; Drug Therap | 1993 |
The third epidemic--multidrug-resistant tuberculosis.
Topics: Adult; Age Factors; Comorbidity; Disease Outbreaks; Drug Resistance, Microbial; Ethambutol; Female; | 1994 |
Acute and long-term efficacy of antituberculous treatment in HIV-seropositive patients with tuberculosis: a study of 36 cases.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antitubercular Agents; Bisexuality; CD4-CD8 Ratio; | 1993 |
Mycobacterial infections in renal allograft recipients.
Topics: Drug Therapy, Combination; Ethambutol; HIV Seropositivity; Humans; Immunosuppressive Agents; Isoniaz | 1993 |
A comparative study of tuberculin skin test reactivity between asymptomatic HIV-1 seropositive subjects and healthy volunteers.
Topics: Adult; Antitubercular Agents; Female; HIV Seropositivity; HIV-1; Humans; Isoniazid; Male; Thailand; | 1995 |
[Multidrug-resistant tuberculosis. Remarks and reflections on a controversial subject of current utmost importance].
Topics: Antitubercular Agents; Drug Resistance, Multiple; HIV Infections; HIV Seronegativity; HIV Seropositi | 1996 |
Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection.
Topics: Adult; Aged; Antitubercular Agents; Case-Control Studies; Diarrhea; Ethambutol; Female; HIV Infectio | 1997 |
How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Drug Admi | 1998 |
A tuberculin screening and isoniazid preventive therapy program in an inner-city population.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Female; HIV Seropositivity; | 1999 |
Tuberculous meningitis and co-infection with HIV.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Child, Preschool; HIV Seronegat | 1998 |
Tuberculosis prevention in methadone maintenance clinics. Effectiveness and cost-effectiveness.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Cost-Benefit Analysis; Drug The | 1999 |
Trends in antituberculosis drug resistance in Karonga District, Malawi, 1986-1998.
Topics: Adult; Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Female; HIV Seropositivity; Hu | 2000 |
CDC changing position on anergy testing, therapy. Centers for Disease Control and Prevention.
Topics: Antitubercular Agents; Clinical Protocols; HIV Seropositivity; Humans; Isoniazid; Risk Factors; Tube | 1997 |
Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Cost-Benefit Analys | 2001 |
Adverse reaction to antimycobacterials administered as a combination tablet with no reaction to the same drugs in isolation.
Topics: Adult; Antitubercular Agents; Drug Combinations; Drug Therapy, Combination; HIV Seropositivity; Huma | 2001 |
Transmission of multidrug-resistant tuberculosis among immunocompromised persons in a correctional system--New York, 1991.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Ethionamide; HIV Seropositivity; Huma | 1992 |
From the Centers for Disease Control. Transmission of multidrug-resistant tuberculosis among immunocompromised persons, correctional system--New York, 1991.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Ethionamide; HIV Seropositivity; Huma | 1992 |
HIV prevalence, immunosuppression, and drug resistance in patients with tuberculosis in an area endemic for AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; CD4-Positive T-Lymphocytes; Drug Resist | 1991 |
Peripheral neuropathy in HIV patient after isoniazid therapy initiated.
Topics: Adult; HIV Seropositivity; Humans; Isoniazid; Male; Peripheral Nervous System Diseases | 1991 |
Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis.
Topics: Adult; Chemical and Drug Induced Liver Injury; Decision Trees; HIV Infections; HIV Seropositivity; H | 1991 |